Related Experiment Videos
[Interleukin-2 based immunotherapy of cancer]
P F Geertsen1, G G Hermann, M H Claësson
1Københavns Amts Sygehus i Herlev.
Ugeskrift for Laeger
|November 19, 1990
Summary
Interleukin-2 (IL-2) therapy shows promise for treating renal cell carcinoma and malignant melanoma but remains experimental. Its use requires specialized centers due to significant side effects like capillary leak syndrome.
Area of Science:
- Immunology
- Oncology
Context:
- Interleukin-2 (IL-2) is a cytokine produced by T-helper lymphocytes.
- IL-2 stimulates both specific and non-specific immune responses.
- In vitro, IL-2 activated lymphocytes can lyse tumor cells.
Purpose:
- To review the clinical applications and limitations of Interleukin-2 (IL-2) therapy.
- To discuss the anti-tumor mechanisms, efficacy, and side effects of IL-2.
Summary:
- Recombinant IL-2 has been used since 1984, often with effector cells or chemotherapy.
- Effective in renal cell carcinoma (35%) and malignant melanoma (24%).
- Significant side effects, including capillary leak syndrome, necessitate careful management.
Impact:
- IL-2 therapy is still considered experimental.
- Treatment should be confined to specialized centers with close collaboration with immunological laboratories.
- Further research is needed to clarify in vivo anti-tumor mechanisms.